Enzyme Inhibitor from Marine Organisms

Marine habitats are promising sources to identify novel organisms and compounds. A total of 70% of the planet's surface is covered by ocean, and little is known about the biosphere within these habitats. In the last few years, numerous novel bioactive compounds or secondary metabolites from mar...

Full description

Saved in:
Bibliographic Details
Other Authors: Tischler, Dirk (Editor)
Format: Book Chapter
Published: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020
Subjects:
Online Access:Get Fullteks
DOAB: description of the publication
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 03339naaaa2200757uu 4500
001 doab_20_500_12854_69424
005 20210501
020 |a books978-3-03943-784-9 
020 |a 9783039437832 
020 |a 9783039437849 
024 7 |a 10.3390/books978-3-03943-784-9  |c doi 
041 0 |a English 
042 |a dc 
072 7 |a GP  |2 bicssc 
100 1 |a Tischler, Dirk  |4 edt 
700 1 |a Tischler, Dirk  |4 oth 
245 1 0 |a Enzyme Inhibitor from Marine Organisms 
260 |a Basel, Switzerland  |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2020 
300 |a 1 electronic resource (130 p.) 
506 0 |a Open Access  |2 star  |f Unrestricted online access 
520 |a Marine habitats are promising sources to identify novel organisms and compounds. A total of 70% of the planet's surface is covered by ocean, and little is known about the biosphere within these habitats. In the last few years, numerous novel bioactive compounds or secondary metabolites from marine environments have been described. This is, and will be, a promising source of candidate compounds in pharma research and chemical biology. In recent years, a number of novel techniques have been introduced to the field and it has become easier to actually (bio-)prospect compounds such as enzyme inhibitors. Those novel compounds then need to be characterized and evaluated in comparison to well-known representatives. This Special Issue focuses on the description of novel enzyme inhibitors of marine origin, including bioprospecting, omic approaches, and structural and mechanistic aspects. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by/4.0/  |2 cc  |4 https://creativecommons.org/licenses/by/4.0/ 
546 |a English 
650 7 |a Research & information: general  |2 bicssc 
653 |a sponge Monanchora pulchra 
653 |a pentacyclic guanidine alkaloids 
653 |a GH36 α-galactosidase 
653 |a GH109 α-N-acetylgalactosaminidase 
653 |a slow-binding irreversible inhibitor 
653 |a monanchomycalin B 
653 |a monanhocidin A 
653 |a normonanhocidin A 
653 |a Alzheimer's disease 
653 |a BACE1 
653 |a acetylcholinesterase 
653 |a in silico docking 
653 |a phlorotannins 
653 |a Ulva intestinalis 
653 |a ACE inhibitory peptide 
653 |a optimization 
653 |a purification 
653 |a structural identification 
653 |a molecular docking 
653 |a secondary metabolites 
653 |a Mycosphaerella sp. 
653 |a asperchalasine 
653 |a α-glucosidase 
653 |a kinase inhibitors 
653 |a drug development 
653 |a marine natural products 
653 |a inhibitor 
653 |a macroalgae 
653 |a marine fish 
653 |a protease 
653 |a Ulva ohnoi 
653 |a functional annotation 
653 |a structure-function relation 
653 |a natural products 
653 |a bioactives 
653 |a enzyme inhibition 
653 |a inactivation 
653 |a marine bacteria 
653 |a marine fungi 
653 |a marine sponges 
856 4 0 |a www.oapen.org  |u https://mdpi.com/books/pdfview/book/3226  |7 0  |z Get Fullteks 
856 4 0 |a www.oapen.org  |u https://directory.doabooks.org/handle/20.500.12854/69424  |7 0  |z DOAB: description of the publication